Project description
Creating in situ drug "factories" for the delivery of biotherapeutics
Nucleic acid therapeutics represent an emerging treatment for unmet medical needs, targeting disease at the genetic level by preventing the expression of disease-causing proteins. One of their characteristics is that they need to be encapsulated in nanocarriers to ensure stability and efficient uptake into cells. A promising nanocarrier for drug delivery is extracellular vesicles (EV), which benefit from immune tolerance as native nanoparticles, and they are also able to cross biological barriers, including the blood–brain barrier. The EU-funded DELIVER project aims to develop synthetic nanocarriers to transiently engineer hepatic cells in vivo and turn them into specific EV-producing "factories" to deliver biotherapeutics to currently unreachable organs. The long-term project goal is to create a platform for in situ EV engineering, enabling the delivery of virtually any biotherapeutic product.
Fields of science
- natural sciencesbiological sciencesneurobiology
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- engineering and technologynanotechnologynano-materials
- medical and health sciencesbasic medicineneurologyparkinson
Call for proposal
ERC-2020-COG
See other projects for this call
Funding Scheme
ERC-COG - Consolidator Grant
Host institution
17177 Stockholm
Sweden
See on map
Beneficiaries (1)
17177 Stockholm
See on map